Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in ...

Related Keywords

Prague ,Praha ,Hlavníesto ,Czech Republic ,Denmark ,Copenhagen ,Køavn ,Ulrich Krasilnikoff ,Curasightas Curasight ,Aleena Azam ,University Of Copenhagen ,World Molecular Imaging Congress ,Primary Gliomas ,Prognostic Value ,Targeted Radionuclide ,Molecular Imaging ,Springer Publisher ,